Bristol-Myers Squibb Company PFD CONV 2 EBIT

As of the most recent data (September 2026), BMYMP shows a EBIT of $14B. That compares with $7.2B in the prior-year period — up 88.2% year over year. That is below the Healthcare sector average of $99B. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, BMYMP's EBIT is now $14B (was $7.2B) — a 88.2% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Bristol-Myers Squibb Company PFD CONV 2 is outperforming or lagging.

The Healthcare sector average EBIT is about $99B. Bristol-Myers Squibb Company PFD CONV 2 is at $14B, which is lower that average. That is roughly 86.3% below the sector mean. Use the comparison chart on this page to see how BMYMP stacks up against individual peers as well.

Tracking BMYMP's ebit over time shows whether Bristol-Myers Squibb Company PFD CONV 2 is scaling, shrinking, or reshaping that part of the business. The current reading is $14B That compares with $7.2B in the prior-year period — up 88.2% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this ebit page, Stockcircle has Bristol-Myers Squibb Company PFD CONV 2's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $14B) with ownership activity and broader fundamentals.